Theriva Capital Stock vs Long Term Debt Analysis

TOVX Stock  USD 1.28  0.02  1.59%   
Theriva Biologics financial indicator trend analysis is much more than just breaking down Theriva Biologics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theriva Biologics is a good investment. Please check the relationship between Theriva Biologics Capital Stock and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Capital Stock vs Long Term Debt

Capital Stock vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theriva Biologics Capital Stock account and Long Term Debt. At this time, the significance of the direction appears to have strong relationship.
The correlation between Theriva Biologics' Capital Stock and Long Term Debt is 0.61. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Theriva Biologics, assuming nothing else is changed. The correlation between historical values of Theriva Biologics' Capital Stock and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Theriva Biologics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Capital Stock i.e., Theriva Biologics' Capital Stock and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.61
Relationship DirectionPositive 
Relationship StrengthSignificant

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Long Term Debt

Long-term debt is a debt that Theriva Biologics has held for over one year. Long-term debt appears on Theriva Biologics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Theriva Biologics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from Theriva Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theriva Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.At this time, Theriva Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.75 in 2024, whereas Selling General Administrative is likely to drop slightly above 7.1 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses14.3M21.6M21.4M13.9M
Cost Of Revenue87K268K135K183.7K

Theriva Biologics fundamental ratios Correlations

0.140.94-0.83-0.760.010.790.730.790.860.460.810.120.84-0.51-0.760.540.90.480.460.53-0.350.36-0.270.510.71
0.14-0.14-0.14-0.20.740.140.00.140.160.790.210.990.15-0.130.060.330.040.04-0.070.11-0.280.270.09-0.13-0.01
0.94-0.14-0.84-0.68-0.180.820.620.820.790.130.81-0.150.72-0.44-0.760.40.820.380.390.33-0.290.29-0.30.630.61
-0.83-0.14-0.840.56-0.01-0.99-0.23-0.99-0.64-0.23-0.98-0.13-0.50.390.55-0.26-0.560.00.01-0.190.32-0.320.06-0.79-0.21
-0.76-0.2-0.680.56-0.16-0.54-0.64-0.54-0.98-0.51-0.55-0.14-0.840.350.83-0.63-0.74-0.53-0.49-0.530.52-0.520.49-0.38-0.62
0.010.74-0.18-0.01-0.160.01-0.130.010.10.550.10.640.030.00.160.24-0.12-0.1-0.150.01-0.230.24-0.02-0.14-0.14
0.790.140.82-0.99-0.540.010.191.00.610.20.990.140.45-0.41-0.530.210.530.0-0.070.16-0.320.3-0.050.780.17
0.730.00.62-0.23-0.64-0.130.190.190.710.480.21-0.020.85-0.45-0.660.590.880.850.80.73-0.20.21-0.39-0.071.0
0.790.140.82-0.99-0.540.011.00.190.610.20.990.140.45-0.41-0.530.210.530.0-0.070.16-0.320.3-0.050.780.17
0.860.160.79-0.64-0.980.10.610.710.610.50.610.10.89-0.38-0.860.650.820.550.540.56-0.490.5-0.470.440.68
0.460.790.13-0.23-0.510.550.20.480.20.50.250.770.57-0.33-0.260.560.450.40.30.69-0.320.33-0.05-0.140.47
0.810.210.81-0.98-0.550.10.990.210.990.610.250.20.46-0.42-0.530.250.540.03-0.050.16-0.350.33-0.070.750.19
0.120.99-0.15-0.13-0.140.640.14-0.020.140.10.770.20.12-0.120.080.30.020.01-0.090.09-0.250.240.13-0.13-0.03
0.840.150.72-0.5-0.840.030.450.850.450.890.570.460.12-0.27-0.740.640.920.710.760.7-0.320.33-0.30.310.83
-0.51-0.13-0.440.390.350.0-0.41-0.45-0.41-0.38-0.33-0.42-0.12-0.270.40.04-0.33-0.160.12-0.420.09-0.090.20.03-0.46
-0.760.06-0.760.550.830.16-0.53-0.66-0.53-0.86-0.26-0.530.08-0.740.4-0.42-0.76-0.52-0.56-0.440.42-0.420.43-0.49-0.65
0.540.330.4-0.26-0.630.240.210.590.210.650.560.250.30.640.04-0.420.660.60.60.45-0.590.61-0.51-0.020.56
0.90.040.82-0.56-0.74-0.120.530.880.530.820.450.540.020.92-0.33-0.760.660.770.750.63-0.440.43-0.420.310.86
0.480.040.380.0-0.53-0.10.00.850.00.550.40.030.010.71-0.16-0.520.60.770.840.59-0.290.21-0.41-0.220.85
0.46-0.070.390.01-0.49-0.15-0.070.8-0.070.540.3-0.05-0.090.760.12-0.560.60.750.840.49-0.20.22-0.34-0.030.8
0.530.110.33-0.19-0.530.010.160.730.160.560.690.160.090.7-0.42-0.440.450.630.590.49-0.130.13-0.09-0.090.72
-0.35-0.28-0.290.320.52-0.23-0.32-0.2-0.32-0.49-0.32-0.35-0.25-0.320.090.42-0.59-0.44-0.29-0.2-0.13-0.980.8-0.11-0.17
0.360.270.29-0.32-0.520.240.30.210.30.50.330.330.240.33-0.09-0.420.610.430.210.220.13-0.98-0.810.120.18
-0.270.09-0.30.060.49-0.02-0.05-0.39-0.05-0.47-0.05-0.070.13-0.30.20.43-0.51-0.42-0.41-0.34-0.090.8-0.810.15-0.38
0.51-0.130.63-0.79-0.38-0.140.78-0.070.780.44-0.140.75-0.130.310.03-0.49-0.020.31-0.22-0.03-0.09-0.110.120.15-0.09
0.71-0.010.61-0.21-0.62-0.140.171.00.170.680.470.19-0.030.83-0.46-0.650.560.860.850.80.72-0.170.18-0.38-0.09
Click cells to compare fundamentals

Theriva Biologics Account Relationship Matchups

Theriva Biologics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets17.2M8.4M70.4M71.9M55.2M58.0M
Total Current Liabilities5.3M3.0M3.6M7.1M6.7M4.2M
Total Stockholder Equity14.4M8.0M65.4M54.6M39.7M41.7M
Net Debt(14.3M)(5.8M)(65.8M)(40.1M)(21.0M)(20.0M)
Retained Earnings(235.5M)(248.1M)(271.3M)(291.0M)(309.3M)(293.9M)
Accounts Payable2.3M886K524K915K770K1.1M
Cash15.0M6.2M67.3M41.8M23.2M12.9M
Non Current Assets Total809K476K1.5M26.3M27.8M29.2M
Cash And Short Term Investments15.0M6.2M67.3M41.8M23.2M13.0M
Liabilities And Stockholders Equity17.2M8.4M70.4M71.9M55.2M58.0M
Other Stockholder Equity232.6M240.8M336.6M343.5M346.2M363.5M
Total Liab5.7M3.2M5.0M17.3M15.5M16.3M
Total Current Assets16.4M7.9M68.9M45.5M27.4M14.4M
Other Current Liab2.7M1.8M2.9M5.7M4.9M3.0M
Property Plant And Equipment Net786K453K1.5M1.5M2.2M2.3M
Non Current Liabilities Total473K186K1.4M10.2M8.8M9.2M
Common Stock17K29K132K16K18K17.1K
Common Stock Shares Outstanding1.6M1.9M12.2M613.1K644.3K1.1M
Net Tangible Assets(2.9M)(7.2M)65.4M46.3M53.3M55.9M
Net Invested Capital(2.9M)(7.2M)65.4M52.1M37.2M28.6M
Capital Stock17.3M15.3M132K2.8M2.8M2.6M
Net Working Capital11.2M5.0M65.3M38.5M20.7M30.6M
Property Plant Equipment786K453K1.5M1.5M1.8M1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.